statement
Lilly's analysis attributed 39.6% of the treatment effect to factors beyond weight loss.
A statement by Lilly. Statements are as reported by the cited publishers — not verified by DecisionGateway.
Lilly's analysis attributed 39.6% of the treatment effect to factors beyond weight loss
Discussion
Related claims
What changes this read: regulators reject the weight-loss-independent analysis, safety or adherence weakens in full publication, or payers restrict coverage despite an approval.MY READ · predictionIf regulators accept the sleep-apnea data, Lilly gains a second disease-specific use for an oral obesity drug and a cleaner pitch to patients who do not want injections.MY READ · predictionThis widens Foundayo's commercial lane beyond weight loss alone.MY READ · predictionAnother 44% depends on estimates without a consistent basis.BCG · statementThe two components act through different and complementary mechanisms of action, jointly acting on appetite and weight-regulation pathways.界面新闻 · statementSeveral factors contributed to the move.cnbc_tv18 · statement